Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation... (designation in Europe for LX1032 provide...)

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

Date:7/21/2009

designation in Europe for LX1032 provides important regulatory and commercial advantages in the development of this new drug candidate for symptoms associated with carcinoid syndrome," said Philip Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "We are now well positioned to conduct trials of LX1032 in Europe as part of an integrated global development strategy."

Lexicon recently initiated a Phase 2 clinical trial of LX1032 in the United States to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome. The study is designed as a four-week, randomized, double-blind, placebo-controlled trial that will include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy. Up to four dose levels may be evaluated in a serial ascending fashion. Once an optimal or maximal dose is identified, additional patients will be added to confirm clinical observations.

In addition to LX1032, Lexicon has three other drug candidates progressing through clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com. LX1031 and LX1032 are being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.

About LX1032

LX1032 was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome. Serotonin's breakdown product, 5-HIAA, i
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
2. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
3. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
4. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
5. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
6. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
7. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
8. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
9. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
10. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
11. AACR Data Highlights InNexus Preclinical Antibody Candidate

Post Your Comments:

(Date:12/16/2009)... -- Today, Avantium announced the,appointment of Gunnar ... pharmaceutical,business. Gunnar Staaf previously worked at Serentis ... Company, in a range of commercial and ... in Avantium,s plan to,spin-out its pharmaceutical business. ... company based on its offering of proprietary,crystallization ...

(Date:12/16/2009)... Dec. 16 GlaxoSmithKline plc [GSK] (NYSE: ... announced an exclusive licensing agreement in the United ... of NB-001, a novel, patented compound representing the ... Developed by NanoBio, NB-001 provides significant antimicrobial activity ... herpes labialis . ,, Cold sores are ...

(Date:12/16/2009)... AARP Illinois Disappointed By Senate Vote Against Lower ... The U.S. Senate on Tuesday night ... Affordable Care Act that would help make prescription ... and legal importation of lower priced drugs from ... and sponsored by Senators Dorgan, Snowe, McCain, Grassley ...

Breaking Medicine Technology:Avantium Appoints Gunnar Staaf as CEO Pharma 2 GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2 AARP Illinois Key Vote News Alert 2 Clinical Studies Validate Cancer Gene Delivery Platform 3A Landmark Publication Confirms Rexin G Effectively Targets Metastatic Cancers and Improves P 49657 1 Clinical Studies Validate Cancer Gene Delivery Platform 3A Landmark Publication Confirms Rexin G Effectively Targets Metastatic Cancers and Improves P 49657 2 Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 12731 1 Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 12731 2 Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 12731 3 Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 12731 4 PhRMA Statement on AARP White House Press Conference 12729 1 PhRMA Statement on AARP White House Press Conference 12729 2

[0] Avantium Appoints Gunnar Staaf as CEO Pharma [0] GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment [0] AARP Illinois Key Vote News Alert

... - Thursday, May 7, 2009 at 5:30 p.m. Eastern TimeMOUNTAIN ... ALXA ) reported today financial results for the quarter ... product candidates. The net loss for the quarter, as ... United States (GAAP), was $6.9 million compared to a net ...

... BCRX ) today announced that an update regarding peramivir ... on Friday, May 8, 2009. Following the release, BioCryst ... a.m. Eastern Time to discuss the financial results and provide ... be led by Jon P. Stonehouse, President and Chief Executive ...

Other Medicine Technology:Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status 2 Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status 3 Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status 4 Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status 5 Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status 6 Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status 7 Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status 8 BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009 2

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009

(Date:12/17/2009)... from MediNiche provide alternative natural relief prior to considering drugs. ... ... December 17, 2009 -- D-Psoria products are the ... associated with severe skin conditions . Developed by ... by MediNiche Pharmaceuticals, St. Louis, Missouri., , ,D-Psoria ...

(Date:12/17/2009)... complex personal injury and insurance cases, recognized for exceptional appellate work ... ... Nexis) December 17, 2009 -- Jody Nathan , a respected ... injury and insurance coverage disputes, has been named by Oklahoma Super ... of Oklahoma for 2009-2010., , ,Only five percent of the lawyers ...

(Date:12/16/2009)... Dec. 17 Health care sector revenue ... trillion, up from $1.66 trillion in 2007, according ... This sector is classified under the North American ... http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) ,, These figures come from ... and Social Assistance , a series of tables ...

(Date:12/16/2009)... Dec. 16 New Enterprise Associates, Inc. ... announced that one of its portfolio companies, Acclarent, ... be acquired by Ethicon, Inc., a Johnson & ... $785 million (net of estimated cash on hand ... dedicated to designing, developing and commercializing devices that ...

(Date:12/16/2009)... WASHINGTON, Dec. 16 Losing has never felt ... knows maintaining his healthy new lifestyle means continuing to ... Drinking fat free milk is one healthy choice that ... a simple step everyone can take. Every glass of ... muscle, potassium to help maintain normal blood pressure, and ...

Breaking Medicine News(10 mins):Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2 Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3 Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4 Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2 Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2 Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3 Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2 Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3

[0] Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin [0] Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List [1] Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 [0] NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon [1] 'The Biggest Loser' Champ Lives Well With Milk

... developed at the University at Buffalo has killed every ... airborne spores, viruses and bacteria in independent tests conducted ... prototype produced by Buffalo BioBlower Technologies LLC, a UB ... better than one part per million in an independent ...

... Dental Experts to Advance ... of CCLAD in Dentistry, LIVINGSTON, N.J., Feb. 28 ... leader in,advanced injection technologies, today reported that earlier this ... (CCLAD) Summit in New Orleans. The Summit welcomed a ...

... Out of Poverty on Average Pays,for Itself and ... LOS ANGELES, Feb. 28 Close to ... today at the Milken,Institute for the West Coast ... the United States economy through proven,investments in children. ...

... motivates people to stay active, helps reduce arthritis ... pain ... announced today a,partnership with McNeil Consumer Healthcare, the maker of TYLENOL(R),Arthritis ... and reduce arthritis pain. Through this new collaboration,participating YMCAs will introduce ...

... was issued by The Mesothelioma Applied Research, Foundation ... House, Energy and Commerce Committee on the "Bruce Vento ... Thursday, February 28, 2008. The Meso,Foundation is urging the ... step-up to the plate in allocating research funds for ...

... Commission Director General for Enterprise & Industry Heinz Zourek today ... an EC budget of 624 million to ESA as a ... , This will be provided in two stages: 419 million ... the GSC programme. Segment 2 will be submitted for subscription ...

Other Medicine News:Health News:UB's bioblower closer to protecting soldiers from biological attack 2 Health News:UB's bioblower closer to protecting soldiers from biological attack 3 Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 2 Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 3 Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 4 Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 5 Health News:Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood 2 Health News:Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood 3 Health News:YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults 2 Health News:YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults 3 Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 2 Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 3 Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 2 Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 3

UB's bioblower closer to protecting soldiers from biological attack Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation Space sentinels: New 'tools' in space to improve European environment and security policies

Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....

Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....

Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....

Retrobulbar Needle, 23 g. Atkinson style bevel. Overall length 38 mm. 5/box....

Medicine Products:

Hydrodissection / Aspiration Cannula, 25 g. Angled Left Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g Irrigating Cystotome, Formed, 23 g Retrobulbar Needle, 23 g. Atkinson style bevel.

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation...(designation in Europe for LX1032 provide...),Health